HPTN 102: LEN in Women (HIV Prevention Medication) (Purpose 3)
Brief description of study
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
HIV Negative
-
Gender: Female
Age: Minimum Age 18
Updated on
08 May 2024.
Study ID: 854195
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting